Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer
(press release) About OVA1
OVA1
is a blood test for pre-surgical assessment of ovarian tumors for
malignancy, using a unique multi-biomarker approach. In a published
clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial
ovarian cancers (EOC). This included 96% sensitivity for stage I EOC,
the earliest and most curable EOC stage, compared with 57% for the
conventional biomarker CA125.(1) In addition, OVA1 found 70% of
malignancies missed by non-specialist pre-surgical assessment,(1) and it
increased detection of malignancy over ACOG guidelines from 77% to
94%.(2) As the first protein-based, In Vitro Diagnostic Multi-Variate
Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new
class of software-based diagnostics.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.